Evidence map›Paper›PMID 32287068›Full record

ArticleAIDS (London, England)2020

Cancer risk following lymphoid malignancies among HIV-infected people.

Parag Mahale, Chinenye Ugoji, Eric A Engels, Meredith S Shiels, Sally Peprah, Lindsay M Morton

Open access · greenAbstract read
In one paragraph

Article in AIDS (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Parag MahaleInfections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda.
Chinenye UgojiDepartment of Epidemiology, Johns Hopkins School of Public Health, Baltimore.
Eric A EngelsInfections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda.
Meredith S ShielsInfections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda.
Sally PeprahInfections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda.
Lindsay M MortonRadiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
National Institutes of Health · USJohns Hopkins University · US

Funding

NATIONAL CANCER PREVENTION AND CONTROL PROGRAMU58DP000824 · DP · TEXAS STATE DEPT OF HEALTH SERVICES · PI DELGADO, EVELYN · 2007 to 2011
$44.3M
NEW YORK STATE CANCER PREVENTION & CONTROL PROGRAMU58DP003879 · DP · NYSDOH/HEALTH RESEARCH, INC. · PI WALLACE, BARBARA J · 2012 to 2014
$37.6M
MICHIGAN CANCER PREVENTION & CONTROL PROGRAMU58DP003921 · DP · MICHIGAN STATE DEPARTMENT OF HEALTH AND HUMAN SERVICES · PI BROOKOVER, PATRICIA · 2012 to 2014
$30.7M
GEORGIA COMPREHENSIVE CANCER CONTROL PROGRAMU58DP003875 · DP · GEORGIA DIVISION OF PUBLIC HEALTH · PI O'CONNOR, JEAN CATHERINE · 2012 to 2014
$15.9M
CANCER PREVENTION & CONTROL PROGRAMS FOR STATE TERRITORIAL & TRIBAL ORGANIZATIONSU58DP003919 · DP · MARYLAND STATE DEPARTMENT OF HEALTH · PI LEWIS, COURTNEY · 2012 to 2014
$15.1M
NEW JERSEY CANCER PREVENTION & CONTROL PROGRAMU58DP003931 · DP · NEW JERSEY STATE DEPT/HEALTH/SENIOR SRVS · PI RODRIQUEZ, GLORIA · 2012 to 2014
$11.9M
INSTITUTIONAL RESEARCH CANCER EPIDEMIOLOGY FELLOWSHIPT32CA009314 · NCI · JOHNS HOPKINS UNIVERSITY · PI Corinne E. Joshu, Meghan Bridgid Moran · 1985 to 2026
$11.2M
National HIV Surveillance SystemU62PS004001 · PS · NEW JERSEY STATE DEPT/HEALTH/SENIOR SRVS · PI BOLDEN, BARBARA JEAN · 2013 to 2016
$8.9M
HIV/AIDS SURVEILLANCEU62PS001005 · PS · CONNECTICUT STATE DEPT OF PUBLIC HEALTH · PI ROOME, AARON · 2008 to 2012
$4.7M
Core and Incidence Surveillance for HIV in MichiganU62PS004011 · PS · MICHIGAN STATE DEPARTMENT OF HEALTH AND HUMAN SERVICES · PI MACOMBER, KATHRYN EMERY · 2013 to 2016
$3.7M
NATIONAL HIV SURVEILLANCE SYSTEM (NHSS)U62PS003960 · PS · COLORADO STATE DEPT/PUB HLTH & ENVIRONMT · PI MATTSON, MELANIE · 2013 to 2016
$2.9M
The Contribution of Systemic Inflammation to Neurocognitive Outcomes, Physiologic Frailty and Mortality in Cancer SurvivorsF31CA246855 · NCI · JOHNS HOPKINS UNIVERSITY · PI UGOJI, CHINENYE · 2019 to 2021
$74k
NCCDPHP CDC HHS U58 DP000824NCCDPHP CDC HHS U58 DP003875NCCDPHP CDC HHS U58 DP003879NCCDPHP CDC HHS U58 DP003919NCCDPHP CDC HHS U58 DP003921NCCDPHP CDC HHS U58 DP003931NCHHSTP CDC HHS U62 PS001005NCHHSTP CDC HHS U62 PS003960NCHHSTP CDC HHS U62 PS004001NCHHSTP CDC HHS U62 PS004011NCI NIH HHS F31 CA246855NCI NIH HHS HHSN261201300019CNCI NIH HHS HHSN261201300019INCI NIH HHS HHSN261201300021CNCI NIH HHS T32 CA009314
6 · The paper itself

Abstract

OBJECTIVE(S): HIV-infected people have increased cancer risk. Lymphoma survivors have an increased risk of certain second primary cancers in the general population, but second cancer risk among HIV-infected people is poorly understood. Herein, we characterized the risk of cancers following lymphoid malignancies among HIV-infected people.

designPopulation-based linkage of HIV and cancer registries.

methodsWe used data from the US HIV/AIDS Cancer Match Study (1996-2015) and evaluated the risk of first nonlymphoid malignancy in Cox regression models, with first lymphoid malignancy diagnosis as a time-dependent variable.

resultsAmong 531 460 HIV-infected people included in our study, 6513 first lymphoid and 18 944 first nonlymphoid malignancies were diagnosed. Risk of nonlymphoid cancer following a lymphoid malignancy was increased overall [adjusted hazard ratio (aHR) = 2.7; 95% confidence interval (CI) = 2.3--3.2], and specifically for cancers of the oral cavity (aHR = 2.6; 95% CI = 1.2-5.5), colon (2.4; 1.1-5.0), rectum (3.6; 1.9-6.7), anus (3.6; 2.5-5.1), liver (2.0; 1.2-3.5), lung (1.6; 1.1-2.4), vagina/vulva (6.1; 2.3-16.3), and central nervous system (5.0; 1.6-15.6), Kaposi sarcoma (4.6; 3.4-6.2), and myeloid malignancies (9.7; 6.1-15.4). After additional adjustment for prior AIDS diagnosis and time since HIV diagnosis, aHRs were attenuated overall (aHR = 1.7; 95% CI = 1.5-2.0) and remained significant for cancers of the rectum, anus, and vagina/vulva, Kaposi sarcoma, and myeloid malignancies.

conclusionHIV-infected people with lymphoid malignancies have an increased risk of subsequent non-lymphoid cancers. As risks remained significant after adjustment for time since HIV diagnosis and prior AIDS diagnosis, it suggests that immunosuppression may explain some, but not all, of these risks.

Indexed as

AdultAgedFemaleHIV InfectionsHumansIncidenceLymphomaMaleMiddle AgedNeoplasmsRisk FactorsSarcoma, KaposiSexual and Gender MinoritiesUnited States

Identifiers

PMID32287068
PMCPMC7382023
OpenAlexW3015630636

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.